inhibitors and interleukin-1 receptor antagonists have been studied in trials using both subcutaneous and intraarticular routes of administration. Efficacy has not been demonstrated, including in erosive hand OA. Therefore, given their known risks of toxicity, we strongly recommended against their use for any form of OA. Initial observations addressing the use of anti-nerve growth factor (anti-NGF) agents suggest that significant analgesic benefits may occur but that incompletely explained